Supplementary information Supplementary Tables 14 Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
"*" indicates required fields Listen to our latest Podcast!
The Jorge study found that GLP-1 RAs were associated with reduced venous thromboembolism risk in lupus patients, which is particularly relevant for those with APS
Some people use it for several months, while others follow longer protocols with periodic monitoring and adjustments to ensure continued safety and effectiveness
Winning the next phase So if efficacy is now table stakes, what will it take to win the next phase